About us
Stimuliver is committed to supporting severly ill liver patients with a regenerative rescue treatment that is independent of donors. Our goal is to provide a groundbreaking alternative for individuals facing liver conditions, offering a comprehensive solution that harnesses the power of regeneration. By pioneering innovative treatments, we strive to improve the lives of patients and empower them with hope and renewed possibilities for better liver health.
Our background
Founded by researchers David Hay and Dagmara Szkolnicka at the University of Edinburgh, our vision is to develop a groundbreaking new therapy for liver diseases, that currently have very limited treatment options. We have developed revolutionary proof of concept data which demonstrates that human liver tissue can be administered subcutaneously in vivo, providing long-term host liver support. Combined with our proprietary technology of differentiating pluripotent stem cells into viable liver tissue, we are developing a scalable off-the-shelf product which uniquely can support the patient’s liver function under the skin.
Meet the team
Teamwork is crucial at Stimuliver. By collaborating, we leverage diverse skills, create a positive work environment, tackle projects efficiently, and promote growth. It's the foundation of our success.
Prof. David Hay, Ph.D.
CEO & Co-founder
20 years’ experience in working with stem cells and their differentiation/engineering toward liver tissue. His team has published over 100 papers in the field which includes four patent applications.
Reinout Hesselink, Ph.D.
CTO
Effective professional in the field of cell and gene therapies, with an emphasis on the CMC and development of cell and gene therapies and their production process from early clinical up to commercial products
Dagmara Szkolnicka, Ph.D.
CSO & Co-founder
Stem cell biologist and virologist with 10 years of international research experience. Established hepatocyte differentiation protocols from stem cells with a wide range of pharma applications and co-authored 20+ papers.
Giles Dudley, Ph.D.
CBO
Experienced in early-stage company formation, seed investment and business development. Established a number of companies and partnerships in the drug discovery space.
Joakim Sørensen, M.Sc.
COO
Several years of experience and proven track-record in business development and operations of early biotech companies, including involvement in the €51m Series A of Adcendo and multiple other fundraisings.
Shruthi Sampath, M.Sc.
Research Scientist
Experienced in stem cell culture and neuronal differentiation. Strong background in molecular biology and bioinformatics.
Justyna Kowal, Ph.D.
Director of Tissue Engineering
Stem cell biologist with a strong international, academic and translational research experience. Co-author of 10+ papers.
Carlos Quintana, M.Sc.
Principal Research Scientist
Experienced in stem cell culture and differentiation, exosome isolation, protein chemistry and neurology. Strong background in molecular biology and pharmaceutical drug development.
